Ian Karp

Ian Karp brings a wealth of experience to Intellia, with more than 20 years of pharmaceutical and biotech experience across investor relations, corporate communications, corporate development and product commercialization. Ian has successfully led global teams at several leading biopharmaceutical companies, with a particular focus in the areas of oncology and orphan diseases. In his role at Intellia, he will lead the Company’s corporate communications activities, including investor and media relations.

Before joining Intellia in July 2021, Ian served as Senior Vice President, Investor and Public Relations at Karyopharm Therapeutics, an oncology-focused pharmaceutical company. In this capacity, he led the communications strategy surrounding the company’s first set of regulatory submissions and approvals in both the U.S. and international markets. Prior to his role at Karyopharm Ian held several positions with increasing responsibility at Shire plc, culminating in his role as Vice President and Head of Global Investor Relations. In addition, Ian served as Shire’s Head of Commercial Assessment and played a critical role in Shire’s corporate acquisition strategy which resulted in company acquisitions totaling more than $40B, including the acquisitions of ViroPharma, Dyax, and Baxalta. Before joining Shire, Ian served as Senior Director for Global Marketing, Emerging Oncology Brands at MedImmune, an AstraZeneca company. Prior to his time at MedImmune, Ian held a variety of sales and marketing positions at Johnson & Johnson’s Centocor division as well as at Pharmacia (now part of Pfizer).

Ian received a Bachelor of Science degree in biology from Emory University and an MBA from Rutgers Business School with a concentration in pharmaceutical management.